Veterinary medicines European public assessment report (EPAR): Nobivac NXT HCPChFeLV, feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (RNA replicon particle) vaccine, Status: Opinion

• Application under evaluation
• CVMP opinion
• European Commission decision

Overview

On 16 April 2026,the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HCPChFeLV, lyophilisate and solvent for suspension for injection, intended for use in cats. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobivac NXT HCPChFeLV is an immunological veterinary medicinal product (vaccine) containing feline herpesvirus 1, strain G2620A (live), feline calicivirus, strain F9 (live), feline panleucopenia virus, strain MW-1 (live), Chlamydia felis, strain Baker (live) and feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA in viral vector, replication deficient as the active substances.

The benefits of Nobivac NXT HCPChFeLV are its efficacy for the active immunisation of cats:

• to reduce mortality, and reduce clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV);
• to reduce the clinical signs and virus excretion caused by infection with feline calicivirus (FCV);
• to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPL);
• to reduce the clinical signs and bacterial excretion caused by infection with Chlamydia felis;
• to reduce persistent viraemia and clinical signs caused by feline leukemia virus (FeLV).

The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination or 3 years after re-vaccination for FHV, FCV and FeLV; 3 years for FPL and 1 year for Chlamydia felis.

Nobivac NXT HCPChFeLV is generally well tolerated at the recommended dose, The most common side effects are injection site swelling and elevated temperature (common).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HCPChFeLV and therefore recommends the granting of the marketing authorisation.

Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

CVMP summary of positive opinion for Nobivac NXT HCPChFeLV

Adopted

Reference Number:

EMA/CVMP/75635/2026

English (EN) (145.15 KB - PDF)

First published:

17/04/2026

View

Product details

Name of medicine

Nobivac NXT HCPChFeLV

Active substance

• feline herpesvirus 1 (FHV), strain G2620A, live
• feline calicivirus (FCV), strain F9, live
• feline panleucopenia virus (FPL), strain MW-1
• chlamydia felis, strain Baker, live
• feline leukemia virus (FeLV) glycoprotein RNA-particle

International non-proprietary name (INN) or common name

feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (RNA replicon particle) vaccine

Species

Cats

EMA product number

EMEA/V/C/006520

Marketing authorisation applicant

Intervet International BV

Opinion adopted

16/04/2026

Opinion status

Positive

News on Nobivac NXT HCPChFeLV

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 April 2026

17/04/2026

EMA recommends authorisation of first veterinary vaccine using RNA technology

17/04/2026

This page was last updated on

17/04/2026